These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9593014)

  • 21. Antibody Response Following Pre-Exposure Immunization Against Rabies in High-Risk Professionals.
    Dougas G; Mavrouli M; Vrioni G; Lytras T; Mellou K; Metallidis S; Istikoglou I; Mitrou K; Tzani M; Georgopoulou I; Tsalikoglou F; Garetsou E; Poulakou G; Giannitsioti E; Moschopoulos C; Baka A; Georgakopoulou T; Tsiodras S; Tsakris A
    Vector Borne Zoonotic Dis; 2020 Apr; 20(4):303-309. PubMed ID: 31794689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax® Rabies) administered in a simulated rabies post-exposure regimen in healthy adults.
    Pichon S; Moureau A; Petit C; Kirstein JL; Sheldon E; Guinet-Morlot F; Minutello AM
    Vaccine; 2024 Apr; 42(10):2553-2559. PubMed ID: 38105138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine.
    Jones RL; Froeschle JE; Atmar RL; Matthews JS; Sanders R; Pardalos J; Moeller L; Chin JE; Famula M; Briggs DJ; Lang J
    Vaccine; 2001 Sep; 19(32):4635-43. PubMed ID: 11535311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody response after a four-site intradermal booster vaccination with cell-culture rabies vaccine.
    Tantawichien T; Benjavongkulchai M; Limsuwan K; Khawplod P; Kaewchompoo W; Chomchey P; Sitprija V
    Clin Infect Dis; 1999 May; 28(5):1100-3. PubMed ID: 10452642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new Vero cell rabies vaccine: results of a comparative trial with human diploid cell rabies vaccine in children.
    Sabchareon A; Lang J; Attanath P; Sirivichayakul C; Pengsaa K; Le Mener V; Chantavanich P; Prarinyanuphab V; Pojjaroen-Anant C; Nimnual S; Wood SC; Riffard P
    Clin Infect Dis; 1999 Jul; 29(1):141-9. PubMed ID: 10433577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preexposure Intradermal Rabies Vaccination: A Noninferiority Trial in Healthy Adults on Shortening the Vaccination Schedule From 28 to 7 Days.
    Soentjens P; Andries P; Aerssens A; Tsoumanis A; Ravinetto R; Heuninckx W; van Loen H; Brochier B; Van Gucht S; Van Damme P; Van Herrewege Y; Bottieau E
    Clin Infect Dis; 2019 Feb; 68(4):607-614. PubMed ID: 29939243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simulated post-exposure rabies vaccination with purified chick embryo cell vaccine using a modified Thai Red Cross regimen.
    Madhusudana SN; Sanjay TV; Mahendra BJ; Suja MS
    Int J Infect Dis; 2004 May; 8(3):175-9. PubMed ID: 15109593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen.
    Ambrozaitis A; Laiskonis A; Balciuniene L; Banzhoff A; Malerczyk C
    Vaccine; 2006 May; 24(19):4116-21. PubMed ID: 16545510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody persistence, 32 years after post-exposure prophylaxis with human diploid cell rabies vaccine (HDCV).
    Fayaz A; Simani S; Janani A; Farahtaj F; Biglari P; Howeizi N; Eslami N
    Vaccine; 2011 May; 29(21):3742-5. PubMed ID: 21458608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection.
    Khawplod P; Wilde H; Sirikwin S; Benjawongkulchai M; Limusanno S; Jaijaroensab W; Chiraguna N; Supich C; Wangroongsarb Y; Sitprija V
    Vaccine; 2006 Apr; 24(16):3084-6. PubMed ID: 16494972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPRV): a two-stage randomised clinical trial in the Philippines.
    Quiambao BP; Lang J; Vital S; Montalban CG; Le Mener V; Wood SC; Miranda E
    Acta Trop; 2000 Feb; 75(1):39-52. PubMed ID: 10708006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of three dose levels of an investigational, highly purified Vero cell rabies vaccine: A randomized, controlled, observer-blinded, Phase II study with a simulated post-exposure regimen in healthy adults.
    Pichon S; Guinet-Morlot F; Saleh J; Essink B; Pineda-Peña AC; Moureau A; Petit C; Minutello AM
    Hum Vaccin Immunother; 2023 Dec; 19(3):2275453. PubMed ID: 37921410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and booster efficacy of pre-exposure rabies vaccination.
    Strady C; Andreoletti L; Baumard S; Servettaz A; Jaussaud R; Strady A
    Trans R Soc Trop Med Hyg; 2009 Nov; 103(11):1159-64. PubMed ID: 19359026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intradermal pre-exposure rabies immunisation in New Zealand.
    Shaw MM; Leggat PA; Williams ML
    Travel Med Infect Dis; 2006 Jan; 4(1):29-33. PubMed ID: 16887722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a post-exposure regimen in healthy children and adults in China.
    Li R; Huang L; Li J; Mo Z; He B; Wang Y; Wu X; Minutello M; Guinet-Morlot F; Pichon S
    Vaccine; 2013 Dec; 31(50):5940-7. PubMed ID: 24148575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of purified Vero-cell rabies vaccine in severely rabies-exposed patients in China.
    Wang XJ; Lang J; Tao XR; Shu JD; Le Mener V; Wood SC; Huang JT; Zhao SL
    Southeast Asian J Trop Med Public Health; 2000 Jun; 31(2):287-94. PubMed ID: 11127328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human diploid cell rabies vaccine. Effectiveness of immunization with small intradermal or subcutaneous doses.
    Bernard KW; Roberts MA; Sumner J; Winkler WG; Mallonee J; Baer GM; Chaney R
    JAMA; 1982 Feb; 247(8):1138-42. PubMed ID: 7057603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Booster effect of human diploid cell antirabies vaccine in previously treated persons.
    Fayaz A; Simani S; Nour-Salehi S; Bahmanyar M
    JAMA; 1981 Nov; 246(20):2334-5. PubMed ID: 7299954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity study of abbreviated rabies preexposure vaccination schedules.
    Khawplod P; Wilde H; Benjavongkulchai M; Sriaroon C; Chomchey P
    J Travel Med; 2007; 14(3):173-6. PubMed ID: 17437473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence of rabies antibody 5 years after pre-exposure prophylaxis with human diploid cell antirabies vaccine and antibody response to a single booster dose.
    Rodrigues FM; Mandke VB; Roumiantzeff M; Rao CV; Mehta JM; Pavri KM; Poonawalla C
    Epidemiol Infect; 1987 Aug; 99(1):91-5. PubMed ID: 3609177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.